Drugs & Aging

, Volume 16, Issue 5, pp 335–339

Chronic Vaginal Candidiasis

Management in the Postmenopausal Patient
Disease Management

DOI: 10.2165/00002512-200016050-00003

Cite this article as:
Nwokolo, N.C. & Boag, F.C. Drugs & Aging (2000) 16: 335. doi:10.2165/00002512-200016050-00003


Vulvovaginal candidiasis (VVC) is a cause of significant morbidity in many women of a childbearing age worldwide.

There is a paucity of literature on the prevalence of this condition in post-menopausal women, although it is believed to be uncommon because of the estrogen dependence of VVC. Postmenopausal women who have underlying risk factors for VVC (e.g. hormone replacement therapy, uncontrolled diabetes mel-litus, immunosuppression caused by medication or disease) may be at risk of chronic or recurrent VVC. However, as in younger women, it is likely that, even after exhaustive investigations, no cause will be found in a significant number of patients.

The investigation and treatment of VVC in older women should be the same as that undertaken in younger women. Both topical and oral preparations are available, but oral regimens are perhaps more acceptable because of the ease of administration and avoidance of potentially messy creams and suppositories. Ketoconazole at a dosage of 400mg daily for 14 days can be used to achieve clinical remission of symptoms and negative fungal cultures. Induction treatment should be followed by maintenance therapy for 6 months with ketoconazole 100mg daily, itraconazole 50 to 100mg daily or fluconazole 100mg weekly or 150mg monthly.

Short courses of topical therapy, e.g. 500mg clotrimazole pessaries as a single weekly dose for 6 months or 100mg miconazole pessaries twice weekly for 3 months, followed by once weekly for 3 months may also be used.

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  1. 1.St Stephen’s CentreChelsea and Westminster HospitalLondonEngland